Press Releases Ypsomed Group

Burgdorf - In business year 2006/07 the Ypsomed Group posted consolidated sales of CHF 277.5 million (-10.7% prior year), returning to profitability as announced in the second half of the year with consolidated net profits of CHF 2.7 million.

Burgdorf - Ypsomed is pleased to announce that it has granted to a major, globally acting pharmaceutical company a non exclusive license to use certain patents, which protect inventions of Ypsomed in the area of auto-injector technology. Ypsomed expects to receive several million Swiss Francs in license fees over the term of the concluded agreement.

Press Releases Ypsomed Group

Burgdorf - After a phase of above average growth in sales and profit the Ypsomed Group is currently in a period of consolidation. In the frist half year 2006/07 (April 1 – September 1 2006) sales fell 8.8% to a total of CHF 129.0 million and a operating loss of CHF 5.3 million.

Press Releases Ypsomed Group

Burgdorf - Ypsomed today has to issue an ad-hoc information due to lower than expected orders for insulin pen systems. Therefore sales and profitability for the business year 2006/07 will be lower than forecasted so far. At the same time Ypsomed announced the change of the CEO.

Press Releases Ypsomed Group

Burgdorf - Ypsomed has resumed production of the dialling unit for the OptiClik pen system as planned following an intensive optimisation phase.